Form 4: Bristol-Myers Squibb Director Acquires Deferred Share Units

Theodore R. Samuels II, a director at Bristol-Myers Squibb, acquired 3,562.341 deferred share units on February 1, 2025, convertible to common stock upon settlement.

Summary

• On February 1, 2025, Theodore R. Samuels II, a director of Bristol-Myers Squibb, acquired 3,562.341 deferred share units.
• These units are convertible into shares of common stock with a par value of $0.10 upon settlement.
• The price per share is $58.95.
• The reporting person's holdings following the transaction include 56,856.466 deferred share units.
• The deferred share units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.
• The holdings include deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of a director's acquisition of deferred share units, which can be seen as a positive sign of confidence but doesn't necessarily indicate a major shift in the company's prospects.

Positives

• The acquisition of deferred share units by a director may signal confidence in the company's future performance.

Future Outlook

The deferred share units will be converted into common stock upon settlement, which occurs when the reporting person ceases to be a director or at a future date previously specified.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. This filing indicates a director's continued investment in the company.

Stakeholder Impact

• The acquisition of deferred share units by a director may be viewed positively by shareholders as it aligns the director's interests with those of the shareholders.

Key Dates

Keywords

Form 4, Bristol-Myers Squibb, Director, Deferred Share Units, Beneficial Ownership, BMY, Securities